First drug-eluting contact lens approved in Japan

Video

Acuvue Theravision with Ketotifen from Johnson & Johnson Vision is the first entry into an anticipated category of drug-eluting contact lenses.

Acuvue Theravision with Ketotifen from Johnson & Johnson Vision is the first entry into an anticipated category of drug-eluting contact lenses. This lens was recently approved in Japan for vision correction and allergy symptom relief. Brian Pall, OD, MS, FAAO, director of clinical science at Johnson & Johnson Vision Care, discusses the lens and its technology.

Recent Videos
In a study, a xenon slide illuminator was employed to mimic natural outdoor colors, allowing researchers to test brightness perception using a brightness-matching method, explains Billy R. Hammond.
Christi Closson, OD, FAAO, provides insight on what other ODs learned about Johnson & Johnson's contact lens technology.
Dana Shannon, OD, FAAO, details The Contact Lens Instiute's latest report, The Dropout Dilemma.
Billy R. Hammond details the study, which explored how HEV-light filtering, specifically in the 380-440 nanometer range, impacts visual comfort for patients with presbyopia.
Erin Tomiyama, OD, PhD, FAAO, discusses fitting lenses, young adults with binocular vision issues, and emerging presbyopia in patients.
Dr Andrew Pucker at the American Academy of Optometry meeting in 2024
Dr. Justin Schweitzer at AAOpt
CLI data presented by Scott Moscow and Andrew Bruce
Jessilin Quint, OD, MBA, FAAO, overviews her presentations at Vision Expo West.
A. Philip Aitsebaomo, O.D., Ph.D. outlines his talk on treating patients with prosthetic eyes
© 2024 MJH Life Sciences

All rights reserved.